Michael Gurevich

Keyphrases

1. Multiple Sclerosis 100%
2. Multiple Sclerosis Treatment 70%
3. Relapsing-remitting multiple Sclerosis 38%
4. COVID-19 26%
5. Gene Expression 19%
6. Cyclooxygenase-1 (COX-1) 17%
7. Glatiramer Acetate 13%
8. Disease Activity 13%
9. Multiple Sclerosis Relapse 13%
10. Polymerase 13%
11. Progressive multiple Sclerosis 12%
12. Luteinizing Hormone 12%
13. Peripheral Blood Mononuclear Cells 12%
14. Gene Signature 12%
15. Disability Progression 11%
16. Expanded Disability Status Scale 11%
17. Convalescent 10%
18. Humoral Immune Response 10%
19. Experimental Autoimmune Encephalomyelitis 10%
20. First Demyelinating Event 9%
21. Disease Progression 9%
22. Immune Response 9%
23. Memory B Cells 9%
24. Prostaglandins 9%
25. Magnetic Resonance Imaging 9%
26. Luteinizing Hormone Receptor 9%
27. Pediatric multiple Sclerosis 9%
28. Remission 9%
29. Liver 8%
30. Restriction Enzyme 8%
31. Prostaglandin E2 8%
32. Fingolimod 8%
33. LH Receptor 8%
34. Acute Relapse 8%
35. COVID-19 Vaccination 8%
36. Disease-modifying Therapy 8%
37. Risk Factors 8%
38. Gene Expression Pattern 7%
39. Estrus 7%
40. Porcine Endometrium 7%
41. Transgenic 7%
42. Differentially Expressed Genes 7%
43. Tumor Necrosis Factor-α 7%
44. Nuclear Receptor 7%
45. Disease Duration 7%
46. Clinically Isolated Syndrome 7%
47. Disability 7%
48. Messenger RNA (mRNA) 7%
49. Gene Expression Analysis 7%
50. Natalizumab 6%